Clinical Trial Update: Safety and Efficacy of Adalimumab in Patients With Moderate to Severely Active Psoriatic Arthritis [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the safety and efficacy of adalimumab in patients with moderate to severely active psoriatic arthritis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis

Drugs mentioned

• Adalimumab (Humira) (adalimumab)

Snippet

Sponsor: Abbott | Conditions: Psoriatic Arthritis | Phase 3 | Status: COMPLETED